Law firm Stephenson Harwood LLP has advised e-therapeutics plc on fundraise of up to £12.4 million.

e-therapeutics is an Oxford-based company which aims to transform the drug discovery process by leveraging its computational power and biological expertise to accelerate the path to identifying and developing effective therapies. The company has developed a proprietary, disease-agnostic platform to produce valuable disease biological insights and potential drug candidates.

The all equity fund raise of up to £12.4 million comprises a firm placing to institutional and other investors, as well an associated broker option available to institutional and other investors in the event of additional demand, direct subscriptions by individual investors based in various overseas jurisdictions, and an offer to retail and other investors via the PrimaryBid platform. Net proceeds will be used to facilitate a number of initiatives to enable the company's next stage of growth and value creation by expanding the company's platform capabilities and asset pipeline.

The team was led by partner Anthony Clare, who was supported by associates Michelle Gomes and Kate Hewitson.

The award-winning Stephenson Harwood life sciences sector group advises clients from across the industry, including pharmaceutical, biotechnology, medical device and diagnostic, and manufacturers, distributors and logistics companies, as well as investors, banks and financial institutions.